RBM6 and neoplasm: In Figure 7, it was observed that RBM6 exhibits inhibitory effects on tumour migration in enzalutamide‐resistant LNCaP cell lines, indicating at the significant potential of RBM6 as a therapeutic target for patients suffering from advanced Castrate‐Resistant Prostate Cancer (CRPC).